Share price · LEXX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LEXX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Sep 2026-38.6%
- 9 Sep 2026-29.6%
- 8 Sep 2026-33.8%
- 13 Aug 2026+32.4%
- 4 Aug 2026+18.3%
Nothing announced by LEXX that day or the session before.
- 3 Aug 2026-19.0%
Nothing announced by LEXX that day or the session before.
- 30 Jul 2026-25.3%
- 17 Jul 2026+13.8%
Nothing announced by LEXX that day or the session before.
- 8 Jul 2026+14.2%
Nothing announced by LEXX that day or the session before.
- 18 Jun 2026-11.6%
Share of unusual movement by asset
For each asset, the share of LEXX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
DehydraTECH-CBDevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 34% |
| Sessions with no dated event | — | 66% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Oral peptide delivery platform · GLP-1 receptorCombination | Obesity | |
| Preclinical / Unstaged | —Small molecule | Hypertension |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $1.0M | $3.5M+ $0.1M short-term inv. | $2.0M-$1.6M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | <$0.1M | $0.5M | $5.1M+ $0.1M short-term inv. | $1.4M-$2.2M operating cash flow | report ↗ |
| 2025-Q4 | $0 | $0.7M | $4.3M+ $0.1M short-term inv. | $1.6M-$1.0M operating cash flow | report ↗ |
| 2025-Q2 | $0.2M | $2.7M | $4.6M+ <$0.1M short-term inv. | $3.8M-$3.6M operating cash flow | report ↗ |
| 2025-Q1 | $0.2M | $1.7M | $6.5M+ $0.1M short-term inv. | $2.7M-$1.5M operating cash flow | report ↗ |
| 2024-Q4 | $0.2M | $1.9M | $8.1M+ <$0.1M short-term inv. | $2.7M-$2.7M operating cash flow | report ↗ |
| 2024-Q2 | $0.1M | $0.6M | $8.5M+ $0.1M short-term inv. | $1.8M-$1.3M operating cash flow | report ↗ |
| 2024-Q1 | $0.1M | $0.3M | $4.7M+ $0.1M short-term inv. | $0.7M-$0.6M operating cash flow | report ↗ |
| 2023-Q4 | $0.1M | $0.6M | $1.9M+ $0.1M short-term inv. | $1.2M-$1.2M operating cash flow | report ↗ |
| 2023-Q2 | $0.1M | $1.6M | $3.2M+ $0.3M short-term inv. | $2.4M-$1.8M operating cash flow | report ↗ |
| 2023-Q1 | <$0.1M | $0.7M | $3.3M+ $0.3M short-term inv. | $1.3M-$1.2M operating cash flow | report ↗ |
| 2022-Q4 | $0.1M | $0.8M | $4.5M+ $0.3M short-term inv. | $1.8M-$1.2M operating cash flow | report ↗ |
| 2022-Q2 | $0.1M | $0.8M | $7.0M+ $0.3M short-term inv. | $2.4M-$1.3M operating cash flow | report ↗ |
| 2022-Q1 | <$0.1M | $0.3M | $8.4M+ $0.6M short-term inv. | $1.4M-$1.3M operating cash flow | report ↗ |
| 2021-Q4 | <$0.1M | $0.5M | $9.7M+ $0.5M short-term inv. | $2.0M-$1.2M operating cash flow | report ↗ |
| 2021-Q3 | — | — | $11M+ $0.8M short-term inv. | $1.2M-$1.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.7M | $8.2M | $1.8M+ $0.1M short-term inv. | $3.0M-$10M operating cash flow | report ↗ |
For fiscal 2025, Lexaria Bioscience reported revenue of $0.71M, up 54.3% YoY, with R&D spend of $8.24M, up 249.2% YoY. Cash and equivalents were $1.8M, and the company reported a net loss of $11.9M with a quarterly net burn of $11.9M.
During the year, Lexaria advanced its DehydraTECH drug-delivery platform across GLP-1/GIP and CBD programs, including human pilot studies of DehydraTECH-enhanced semaglutide, liraglutide, and tirzepatide, and reached last patient last visit in the chronic human study GLP-1-H24-4, with preliminary 8-week data showing reduced gastrointestinal adverse events versus Rybelsus. The company’s IND for DehydraTECH-CBD in hypertension remains active following an FDA Study May Proceed letter. It also expanded its patent portfolio, including diabetes, epilepsy, nicotine, and food and beverage patents, and maintained various licensing arrangements, with the Premier non-exclusive license expiring August 31, 2025.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.5M | $2.4M | $6.5M+ $0.1M short-term inv. | $1.4M-$5.0M operating cash flow | report ↗ |
| 2023-FY | $0.2M | $3.7M | $1.4M+ $0.1M short-term inv. | $1.7M-$5.9M operating cash flow | report ↗ |
| 2022-FY | $0.3M | $1.8M | $5.8M+ $0.3M short-term inv. | $1.8M-$4.9M operating cash flow | report ↗ |
| 2021-FY | $0.7M | $1.3M | $11M+ $0.8M short-term inv. | $1.1M-$4.0M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-03-17 | BUNKA CHRISTOPHER · director | Gift | 100,000 | — | — | Form 4 |
| 2025-07-30 | BUNKA CHRISTOPHER · director | Open-market purchase | 11,900 | $0.91 | $11K | Form 4 |
| 2025-07-29 | CHRISTOPHER RICHARD · director, Chief Executive Officer | Open-market purchase | 15,000 | $0.91 | $14K | Form 4 |
| 2025-07-29 | Carle Vanessa · Secretary | Open-market purchase | 750 | $0.91 | $683 | Form 4 |
| 2025-07-29 | DOCHERTY JOHN MARTIN · director, President & CSO | Open-market purchase | 5,376 | $0.93 | $5K | Form 4 |
| 2025-07-29 | McKechnie William Edward · director | Open-market purchase | 5,000 | $0.91 | $5K | Form 4 |
| 2025-07-29 | BUNKA CHRISTOPHER · director | Open-market purchase | 15,600 | $0.92 | $14K | Form 4 |
| 2025-05-15 | McKechnie William Edward · director | Award / grant (derivative) | 11,000 | — | — | Form 4 |